These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37997665)

  • 1. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
    Rose AM; Nicolay N; Sandonis Martín V; Mazagatos C; Petrović G; Baruch J; Denayer S; Seyler L; Domegan L; Launay O; Machado A; Burgui C; Vaikutyte R; Niessen FA; Loghin II; Husa P; Aouali N; Panagiotakopoulos G; Tolksdorf K; Horváth JK; Howard J; Pozo F; Gallardo V; Nonković D; Džiugytė A; Bossuyt N; Demuyser T; Duffy R; Luong Nguyen LB; Kislaya I; Martínez-Baz I; Gefenaite G; Knol MJ; Popescu C; Součková L; Simon M; Michelaki S; Reiche J; Ferenczi A; Delgado-Sanz C; Lovrić Makarić Z; Cauchi JP; Barbezange C; Van Nedervelde E; O'Donnell J; Durier C; Guiomar R; Castilla J; Jonikaite I; Bruijning-Verhagen PC; Lazar M; Demlová R; Wirtz G; Amerali M; Dürrwald R; Kunstár MP; Kissling E; Bacci S; Valenciano M; ; ;
    Euro Surveill; 2023 Nov; 28(47):. PubMed ID: 37997665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
    Rose AM; Nicolay N; Sandonis Martín V; Mazagatos C; Petrović G; Niessen FA; Machado A; Launay O; Denayer S; Seyler L; Baruch J; Burgui C; Loghin II; Domegan L; Vaikutytė R; Husa P; Panagiotakopoulos G; Aouali N; Dürrwald R; Howard J; Pozo F; Sastre-Palou B; Nonković D; Knol MJ; Kislaya I; Luong Nguyen LB; Bossuyt N; Demuyser T; Džiugytė A; Martínez-Baz I; Popescu C; Duffy R; Kuliešė M; Součková L; Michelaki S; Simon M; Reiche J; Otero-Barrós MT; Lovrić Makarić Z; Bruijning-Verhagen PC; Gomez V; Lesieur Z; Barbezange C; Van Nedervelde E; Borg ML; Castilla J; Lazar M; O'Donnell J; Jonikaitė I; Demlová R; Amerali M; Wirtz G; Tolksdorf K; Valenciano M; Bacci S; Kissling E; ; ;
    Euro Surveill; 2023 Nov; 28(47):. PubMed ID: 37997666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
    Antunes L; Mazagatos C; Martínez-Baz I; Gomez V; Borg ML; Petrović G; Duffy R; Dufrasne FE; Dürrwald R; Lazar M; Jancoriene L; Oroszi B; Husa P; Howard J; Melo A; Pozo F; Pérez-Gimeno G; Castilla J; Machado A; Džiugytė A; Karabuva S; Fitzgerald M; Fierens S; Tolksdorf K; Popovici SO; Mickienė A; Túri G; Součková L; Nicolay N; Rose AM;
    Euro Surveill; 2024 Jan; 29(3):. PubMed ID: 38240061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
    Lanièce Delaunay C; Martínez-Baz I; Sève N; Domegan L; Mazagatos C; Buda S; Meijer A; Kislaya I; Pascu C; Carnahan A; Oroszi B; Ilić M; Maurel M; Melo A; Sandonis Martín V; Trobajo-Sanmartín C; Enouf V; McKenna A; Pérez-Gimeno G; Goerlitz L; de Lange M; Rodrigues AP; Lazar M; Latorre-Margalef N; Túri G; Castilla J; Falchi A; Bennett C; Gallardo V; Dürrwald R; Eggink D; Guiomar R; Popescu R; Riess M; Horváth JK; Casado I; García MDC; Hooiveld M; Machado A; Bacci S; Kaczmarek M; Kissling E;
    Euro Surveill; 2024 Mar; 29(13):. PubMed ID: 38551095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Masuda S; Osawa R; Hosokawa N; Nakashima K; Kamura H; Imura H; Inoue H; Matsuzaka S; Sugimoto Y; Kuwamitsu O; Motohashi I; Morikawa T; Oda R; Hoshina Y; Matono T; Teshigahara O; Sando E; Asami S; Kudo S; Akizuki N; Muto Y; Hayakawa T; Kishaba T; Ohara Y; Kubo Y; Suzuki M; Morimoto K
    Expert Rev Vaccines; 2024; 23(1):213-225. PubMed ID: 38288980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Bennett JC; Luiten KG; O'Hanlon J; Han PD; McDonald D; Wright T; Wolf CR; Lo NK; Acker Z; Regelbrugge L; McCaffrey KM; Pfau B; Stone J; Schwabe-Fry K; Lockwood CM; Guthrie BL; Gottlieb GS; Englund JA; Uyeki TM; Carone M; Starita LM; Weil AA; Chu HY
    Vaccine; 2024 Feb; 42(6):1332-1341. PubMed ID: 38307746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
    Laniece Delaunay C; Mazagatos C; Martínez-Baz I; Túri G; Goerlitz L; Domegan L; Meijer A; Rodrigues AP; Sève N; Ilic M; Latorre-Margalef N; Lazar M; Maurel M; Melo A; Andreu Ivorra B; Casado I; Horváth JK; Buda S; Bennett C; de Lange M; Guiomar R; Enouf V; Mlinaric I; Samuelsson Hagey T; Dinu S; Rumayor M; Castilla J; Oroszi B; Dürrwald R; O'Donnell J; Hooiveld M; Gomez V; Falchi A; Kurecic Filipovic S; Dillner L; Popescu R; Bacci S; Kaczmarek M; Kissling E;
    JAMA Netw Open; 2024 Jul; 7(7):e2419258. PubMed ID: 38949812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
    Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC
    BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.